AMPH Stock Overview
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France.
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 4/6 |
| Past Performance | 6/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Amphastar Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$41.11 |
| 52 Week High | US$67.66 |
| 52 Week Low | US$35.62 |
| Beta | 0.84 |
| 1 Month Change | -5.54% |
| 3 Month Change | -23.70% |
| 1 Year Change | 14.93% |
| 3 Year Change | 136.26% |
| 5 Year Change | 83.94% |
| Change since IPO | 310.69% |
Recent News & Updates
Recent updates
Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Pretty Healthy Balance Sheet
Mar 27
Why Amphastar Pharmaceuticals Is A Strong Buy: Growth, Valuation, And Strategic Acquisitions
Mar 04Here's Why We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Might Deserve Your Attention Today
Jan 04Why Investors Shouldn't Be Surprised By Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) P/E
Dec 20Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Rock Solid Balance Sheet
Dec 03Amphastar Pharmaceuticals (NASDAQ:AMPH) Ticks All The Boxes When It Comes To Earnings Growth
Sep 18An Intrinsic Calculation For Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Suggests It's 35% Undervalued
Sep 03These 4 Measures Indicate That Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Using Debt Safely
Aug 17Here's Why We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Well Worth Watching
Jun 02We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Can Manage Its Debt With Ease
May 11Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Intrinsic Value Is Potentially 51% Above Its Share Price
Mar 02Is Now The Time To Put Amphastar Pharmaceuticals (NASDAQ:AMPH) On Your Watchlist?
Feb 07Does Amphastar Pharmaceuticals (NASDAQ:AMPH) Have A Healthy Balance Sheet?
Jan 24Here's Why Amphastar Pharmaceuticals (NASDAQ:AMPH) Has Caught The Eye Of Investors
Nov 02Amphastar: A Pharmaceutical Growth Stock
Oct 06Amphastar wins FDA approval for Epinephrine pre-filled syringes
Aug 16Amphastar Pharmaceuticals: Compelling Growth Prospects For H2 2022 And Beyond
Aug 08Do Amphastar Pharmaceuticals' (NASDAQ:AMPH) Earnings Warrant Your Attention?
Jul 24Amphastar generic vasopressin for increasing blood pressure gets FDA approval
Jul 19We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Can Manage Its Debt With Ease
Jun 10Amphastar Pharmaceuticals: Stock With An Attractive 6 To 1 Risk-Reward Ratio
May 13I Ran A Stock Scan For Earnings Growth And Amphastar Pharmaceuticals (NASDAQ:AMPH) Passed With Ease
Apr 23These 4 Measures Indicate That Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Using Debt Safely
Feb 13Amphastar Pharma: A Well-Run, Diversified Mid Cap
Jan 26Should You Be Adding Amphastar Pharmaceuticals (NASDAQ:AMPH) To Your Watchlist Today?
Jan 08Shareholder Returns
| AMPH | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 2.7% | -0.6% | 1.0% |
| 1Y | 14.9% | 10.6% | 21.9% |
Return vs Industry: AMPH matched the US Pharmaceuticals industry which returned 13.2% over the past year.
Return vs Market: AMPH underperformed the US Market which returned 24.9% over the past year.
Price Volatility
| AMPH volatility | |
|---|---|
| AMPH Average Weekly Movement | 5.8% |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: AMPH's share price has been volatile over the past 3 months.
Volatility Over Time: AMPH's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 1,761 | Jack Zhang | www.amphastar.com |
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures.
Amphastar Pharmaceuticals, Inc. Fundamentals Summary
| AMPH fundamental statistics | |
|---|---|
| Market cap | US$2.01b |
| Earnings (TTM) | US$137.55m |
| Revenue (TTM) | US$644.40m |
14.6x
P/E Ratio3.1x
P/S RatioIs AMPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AMPH income statement (TTM) | |
|---|---|
| Revenue | US$644.40m |
| Cost of Revenue | US$290.57m |
| Gross Profit | US$353.82m |
| Other Expenses | US$216.28m |
| Earnings | US$137.55m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.81 |
| Gross Margin | 54.91% |
| Net Profit Margin | 21.34% |
| Debt/Equity Ratio | 92.2% |
How did AMPH perform over the long term?
See historical performance and comparison